Ozempic’s hidden bonus: massive study of 100,000 patients finds semaglutide cuts depression risk by 44% and slashes hospitalisations for anxiety and substance abuse

Semaglutide, the active compound in Ozempic and related medications, is drawing attention beyond weight management after a large observational study of roughly 100,000 patients linked its use to lower rates of depression and fewer hospitalizations for anxiety and substance use disorders. Researchers reported a 44% reduction in depression risk among users compared with similar patients not taking the drug.

Large observational findings on mental health outcomes

Researchers analyzing insurance and clinical records examined outcomes in about 100,000 adults prescribed semaglutide or comparable therapies.

The analysis reported a 44% lower risk of depression and fewer hospital admissions linked to anxiety and substance use disorders among users. overall patterns remained consistent across subgroups.

Signals of reduced anxiety-related hospitalisation

Pooled data suggested lower rates of hospital care for anxiety-related conditions among patients using semaglutide compared with matched controls.

Researchers cautioned that observational design limits conclusions about causation, though the association persisted after adjustments for baseline health differences in the dataset.

Substance use disorder outcomes among patients

Across the cohort, semaglutide users showed fewer hospital admissions related to alcohol and other substance use disorders compared with non-users receiving standard care.

Researchers noted potential metabolic and neurological pathways under investigation, but emphasized that findings remain preliminary and require further validation.

Mechanisms under scientific investigation

Scientists are examining whether GLP-1 receptor activity in the brain may influence mood regulation and reward pathways.

Early laboratory and clinical evidence remains mixed, with some studies suggesting benefits while others show no clear psychiatric effect recently in controlled settings.

Caution in interpreting observational results

Experts stress that observational studies cannot establish causation, as underlying health status, weight change, and concurrent medications may influence outcomes.

Randomized trials are needed to determine whether semaglutide directly contributes to improvements in mood and reductions in psychiatric hospitalisation risk.